AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.

FDA grants Gilead two first-line approvals for Trodelvy in triple-negative breast cancer, broadening its reach beyond Datroway's narrower indication.

AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.